Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did.
Two things I would like separated before anyone answers on Semaglutide and alcohol, because they get bundled and then argued about as one thing.
The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.
Adding the measurement that the opening post says would settle it.
The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
On the opening post — agreed on the reasoning, with one qualification.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
That is what I would do. It may not be what is correct.
Picking up post #5: that is the part I would want checked first.
Semaglutide and alcohol is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
That holds under the stated conditions and I have stated them.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
Following, with nothing to contribute beyond having asked the same thing elsewhere.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Confirming post #10 from a second method, which matters more than confirming it from a second person.
An update on my earlier Semaglutide and alcohol post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Distinguishing three things in the Semaglutide and alcohol discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
I have said this before in a thread nobody could find, so it is worth repeating.
Post #12 describes the usual case. This is about the unusual one.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Old habit: I write down the expected answer before I calculate it.
Post #13 is the version of this I will quote in future. One addition.
STEP 1 and STEP 4 are two different questions. The first asks what happens when treatment is added; the second asks what happens when it is withdrawn after a run-in. Quoting the first as evidence about maintenance is the commonest misreading of the programme.
I have deliberately not rounded that, because the rounding is where the argument starts.
Where I part company with post #12, and it is a narrow parting.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
The rule of thumb is fine; the edge cases are where it earns its keep.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
A qualification I should have led with rather than closed on.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…
|
+61 | 65 | 1.3k | 22mo |
|
What the published dose-response for semaglutide actually looks like above 2.4 mg
What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people here…
|
2 | 10k | 3mo | |
|
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a question…
|
+112 | 119 | 3.3k | 11mo |
|
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+101 | 110 | 12k | 16h |
|
Tracking semaglutide's approved indications across jurisdictions, dated
Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
|
+15 | 19 | 2.8k | 1d |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What the published dose-response for semaglutide actually looks like above 2.4 mg
What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people here…
|
2 | 10k | 3mo | |
|
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be
The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…
|
+109 | 124 | 31k | 10mo |
|
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. A methods question rather than a substantive one, about Criticising…
|
+16 | 20 | 61k | 11mo |
|
Journal club: STEP 4 and what a withdrawal design can prove — one year on
Journal club: STEP 4 and what a withdrawal design can prove — one year on Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 4 ( JAMA , 2021). Please read…
|
+56 | 62 | 34k | 15mo |
|
About the Statistics category
Effect sizes, intervals, multiplicity, and the difference between absent and undetected. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+4 | 8 | 2.3k | 7mo |